Regulatory B Cell
Regulatory B cells (Breg cells) are immunosuppressive B-lymphocyte subsets—including CD1dhigh CD5+ B10 cells, CD24high CD38high transitional B cells, and regulatory plasmablasts—that restrain T-cell-mediated autoimmunity, allergy, and transplant rejection by secreting interleukin-10 (IL-10), IL-35, and TGF-β.
Regulatory B cells (Breg cells) are functionally specialized, immunosuppressive subsets of B lymphocytes and antibody-secreting plasmablasts that negatively regulate cellular immune responses, restrain pathogenic TH1 and TH17 inflammation, promote the differentiation of Foxp3+ regulatory T cells and type 1 regulatory T cells (Tr1), and maintain systemic and mucosal peripheral tolerance. Unlike Foxp3+ regulatory T cells—which constitute a dedicated thymic- or periphery-committed lineage governed by a single master transcription factor—regulatory B cells do not express a unique lineage-restricted transcription factor analogous to Foxp3. Instead, diverse B-cell subsets at distinct developmental stages (including murine splenic CD1dhighCD5+ B10 cells, TIM-1+ B cells, transitional 2 marginal-zone precursor [T2-MZP] B cells, human CD19+CD24highCD38high immature transitional B cells, CD24highCD27+ memory B cells, and CD138+LAG-3+ regulatory plasmablasts) acquire regulatory function in response to Toll-like receptor (TLR4, TLR9), B-cell receptor (BCR), and CD40 co-stimulation coupled with inflammatory cytokines (IL-21, IL-1β, IL-6, and BAFF/APRIL). Activated Breg cells suppress autoimmunity, contact hypersensitivity, and allograft rejection primarily by secreting interleukin-10 (IL-10), interleukin-35 (IL-35), and transforming growth factor-beta (TGF-β), alongside contact-dependent checkpoint engagement via PD-L1, FasL, and GITRL.
Historical Discovery and Phenotypic Diversity of Breg Subsets
From Delayed-Type Hypersensitivity Suppression to the "Regulatory B Cell" Concept
The observation that B cells can suppress rather than amplify immune inflammation dates back to 1974, when Stephen I. Katz, Darien Parker, and John L. Turk demonstrated that splenocytes depleted of B lymphocytes failed to transfer suppression of delayed-type contact hypersensitivity in guinea pigs. In 1996, Charles A. Janeway Jr. and Bonnie N. Dittel showed that B-cell-deficient (μMT) mice immunized with myelin basic protein developed chronic, unremitting experimental autoimmune encephalomyelitis (EAE) that failed to undergo spontaneous recovery. Between 2000 and 2002, Akira Mizoguchi and Atul K. Bhan (who coined the term "regulatory B cells" in inflammatory bowel disease models) and Claudia Mauri and Simon Fillatreau (in collagen-induced arthritis and EAE) proved that selective deletion of the Il10 gene within the B-cell compartment fully replicated the non-recovering autoimmune phenotype of B-cell-deficient mice, establishing B-cell-derived IL-10 as the cardinal mediator of humoral immune regulation.
Major Murine and Human Regulatory B-Cell Populations
Because multiple developmental stages of the B-cell lineage can be induced to transcribe Il10, Ebi3/Il12a (encoding IL-35), or Tgfb1, immunologists classify Breg cells by their anatomical origin and surface markers:
- Splenic B10 Cells (CD19highCD1dhighCD5+, Mouse): Characterized in 2008 by Thomas F. Tedder and colleagues, B10 cells (named for their exclusive competence to produce IL-10 without IL-4 or TNF-α bursts) represent 1% to 2% of splenic B cells in naive mice and share overlapping surface markers with both CD1dhigh marginal zone B cells and CD5+ peritoneal B-1 cells.
- Transitional 2 Marginal Zone Precursor (T2-MZP, CD19+CD21highCD23highCD24highIgMhigh, Mouse) and Immature Transitional (CD19+CD24highCD38high, Human) B Cells: Identified by Claudia Mauri, these immature splenic emigrants expand in response to gut-microbiota-induced IL-1β and IL-6, suppress CD4+ T-cell IFN-γ/TNF-α production, and convert naive CD4+ T cells into Foxp3+ Treg and IL-10+ Tr1 cells.
- TIM-1+ (HAVCR1+) B Cells: Defined by David M. Rothstein and Vijay K. Kuchroo, the phosphatidylserine receptor TIM-1 marks over 70% of all IL-10-producing B cells across splenic subsets; binding of TIM-1 to phosphatidylserine exposed on apoptotic cells directly triggers Breg IL-10 secretion to promote allograft tolerance.
- Regulatory Plasmablasts and Natural Regulatory Plasma Cells (CD138+CD44highBlimp-1+IRF4+, and LAG-3+CD200+PD-L1+): Discovered by Masayuki Matsumoto (2014) and Simon Fillatreau (2014–2018), a major fraction of in vivo IL-10 and IL-35 during Salmonella infection and EAE is produced not by resting B cells, but by short-lived Blimp-1+IRF4+ plasmablasts in draining lymph nodes and LAG-3+ natural regulatory plasma cells in the spleen and bone marrow.
| Breg Subset | Species & Primary Niche | Canonical Surface Phenotype | Key Inducing Signals | Primary Suppressive Effectors |
|---|---|---|---|---|
| B10 Cells | Mouse (Spleen & peritoneal cavity) | CD19hi CD1dhi CD5+ IgMhi CD21int/hi | TLR4 (LPS) / TLR9 (CpG) → BCR + CD40 + IL-21 | IL-10, FasL, suppression of dendritic cell IL-12 |
| T2-MZP Breg Cells | Mouse (Splenic white-pulp border) | CD19+ CD21hi CD23hi CD24hi IgMhi IgDhi CD93+ | BCR + CD40 + BAFF, microbiota-driven IL-1β + IL-6, AhR | IL-10, induction of Foxp3+ Treg & Tr1 cells |
| Immature Transitional Breg | Human (Peripheral blood & secondary lymphoid organs) | CD19+ CD24hi CD38hi IgMhi IgD+ CD27− | CD40L (from T cells), TLR9, IFN-α (from pDCs in low dose) | IL-10, TGF-β, CD80/CD86–CTLA-4 Treg licensing |
| B10 / Memory Breg | Human (Blood, tonsils, spleen) | CD19+ CD24hi CD27+ or CD25+ CD71+ CD73+ (BR1) | TLR9 + CD40 + BCR; allergen immunotherapy | IL-10, IgG4 (non-inflammatory blocking antibody), Adenosine |
| Regulatory Plasmablasts / PCs | Mouse & Human (Draining lymph nodes, spleen, CNS) | CD138+ CD44hi Blimp-1+ IRF4+ (or LAG-3+ PD-L2+) | BCR + TLR4/9 + CD40 + IL-21 (STIM1/2 Ca2+–NFAT) | IL-10 and heterodimeric IL-35 (EBI3 + p35) |
Two-Step Activation Cascade and Transcriptional Regulation of Il10
TLR Poising Followed by Cognate BCR + CD40 + IL-21 Licensing
Resting B cells do not constitutively secrete high levels of IL-10; rather, functional maturation from a poised B10 progenitor (B10PRO) into an actively secreting B10 effector cell follows a two-step innate-to-adaptive licensing cascade:
- Step 1 — Innate Toll-Like Receptor and Microbiota Priming: Recognition of bacterial lipopolysaccharide via TLR4 or unmethylated CpG DNA via TLR9 (signaling through the adaptor MyD88 and activating STAT3 and NF-κB) epigenetically remodels the Il10 locus in B10PRO cells. In the gut-associated lymphoid tissue and spleen, short-chain fatty acids (butyrate and propionate) and tryptophan-derived 5-hydroxyindole-3-acetic acid (5-HIAA) produced by commensal bacteria of the human microbiome activate the aryl hydrocarbon receptor (AhR) in T2-MZP B cells; as shown by Claudia Mauri (2018–2020), AhR binds directly to the Il10 locus while suppressing pro-inflammatory cytokine genes (Il6, Tnf) to maintain Breg identity.
- Step 2 — Cognate BCR + CD40 + IL-21 Amplification: When TLR-poised Breg precursors encounter self-antigen or microbial antigen through their BCR and present peptide–MHC class II to activated CD4+ T cells, T-cell CD40L (CD154) and IL-21 engage B-cell CD40 and IL-21R. BCR cross-linking triggers endoplasmic reticulum calcium depletion sensed by STIM1 and STIM2, opening ORAI1 store-operated calcium entry (SOCE) channels to activate calcineurin and NFATc1. Simultaneously, IL-21R activates STAT3, and CD40 activates ERK/p38 MAPK and CREB. Cooperative binding of STAT3, NFATc1, c-Maf, AhR, Blimp-1, and IRF4 across the Il10 promoter and distal enhancers drives a 10- to 50-fold surge in IL-10 and IL-35 secretion.
Molecular Mechanisms of Immune Suppression and Clinical Relevance
Soluble Mediators: IL-10, IL-35, TGF-β, Adenosine, and IgG4
Once licensed, Breg cells restrain adaptive and innate immune responses through five complementary molecular pathways:
- Interleukin-10 (IL-10): Breg-derived IL-10 acts on dendritic cells and macrophages via IL-10R/STAT3 to downregulate MHC class II, CD80/CD86, IL-12, IL-23, and TNF-α, blocking the priming of pathogenic TH1 and TH17 cells while promoting the expansion of Foxp3+ Treg, follicular regulatory T cells (TFR), and IL-10-producing type 1 regulatory T cells (Tr1), and inhibiting invariant natural killer T cell hyperactivation via CD1d lipid presentation.
- Interleukin-35 (IL-35): Identified in Breg cells and CD138+ regulatory plasmablasts by Simon Fillatreau and Charles E. Egwuagu (2014), IL-35 is an immunosuppressive heterodimer of EBI3 (Epstein-Barr virus-induced gene 3) and IL-12p35 (Il12a). B-cell-derived IL-35 signals through a heterodimer of IL-12Rβ2 and gp130 (or IL-27Rα/IL-12Rβ2 on B cells) to activate STAT1–STAT4 and STAT1–STAT3 heterodimers, arresting pathogenic T-cell proliferation and converting conventional B and T cells into secondary IL-35- and IL-10-producing regulatory cells via infectious tolerance.
- TGF-β, Pericellular Adenosine (CD39/CD73), and Blocking IgG4: Subsets of human Breg cells co-express the ectonucleotidases CD39 and CD73, which hydrolyze pro-inflammatory extracellular ATP into immunosuppressive adenosine (which engages A2A receptors on effector T cells). In human allergen-specific immunotherapy (such as bee-venom or peanut desensitization), Cezmi A. Akdis demonstrated that IL-10-producing BR1 cells selectively undergo class switch recombination to IgG4—a monovalent, Fab-arm-exchanging antibody isotype that cannot fix complement or cross-link mast-cell FcεRI, thereby blocking allergen-induced anaphylaxis.
- Contact-Dependent Cytolysis and Checkpoints (PD-L1, FasL, Granzyme B): PD-L1high Breg cells directly inhibit PD-1+ follicular helper T cells and effector T cells, while CD5+FasL+ killer Breg cells and IL-21-induced Granzyme B+ human Breg cells induce apoptosis of autoreactive CD4+ T cells.
Clinical Paradox in Autoimmunity, Transplantation, and B-Cell Depletion Therapy
Defects in Breg number or function play a central role in human autoimmune diseases and transplant medicine:
- Systemic Lupus Erythematosus (SLE) and Rheumatoid Arthritis: In patients with active SLE, circulating CD19+CD24highCD38high immature transitional B cells are numerically present but are functionally refractory to CD40 and TLR9 stimulation due to chronic exposure to high concentrations of IFN-α produced by plasmacytoid dendritic cells, resulting in impaired STAT3 phosphorylation, loss of IL-10 production, and unrestrained expansion of pathogenic age-associated B cells.
- Operational Tolerance in Renal Transplantation: Rare kidney transplant recipients who maintain stable graft function without lifelong pharmacological immunosuppression (operationally tolerant patients) exhibit a striking peripheral blood expansion of IL-10+CD24highCD38high transitional Breg cells compared to patients suffering chronic allograft rejection.
- The Anti-CD20 (Rituximab) Depletion Paradox: Because therapeutic anti-CD20 monoclonal antibodies (rituximab, ocrelizumab) deplete both pathogenic memory B cells and protective CD20+ Breg cells (while sparing CD20− long-lived plasma cells), timing of B-cell depletion is clinically decisive: in murine EAE, depleting CD20+ B cells before disease induction eliminates protective B10 cells and exacerbates neuroinflammation, whereas depleting CD20+ B cells during established disease removes antigen-presenting pathogenic B cells and allows the subsequent repopulation of the peripheral blood compartment with naive and IL-10-competent CD24highCD38high transitional Breg cells, heralding long-term clinical remission.
Frequently Asked Questions
Do regulatory B cells express Foxp3 or a single master transcription factor?
No. Unlike regulatory T cells—whose identity is governed by the master transcription factor Foxp3—regulatory B cells (Breg) do not express Foxp3 or any single lineage-restricted master regulator. Instead, multiple B-cell subsets (including B10 cells, T2-MZP cells, CD24highCD38high transitional B cells, and CD138+ plasmablasts) activate a shared immunosuppressive transcriptional module driven by STAT3, AhR, c-Maf, NFATc1, IRF4, and Blimp-1 when stimulated by Toll-like receptor ligands, CD40L, and cytokines such as IL-21 or IL-1β/IL-6.
How does interleukin-35 produced by regulatory plasmablasts suppress autoimmune disease?
Interleukin-35 (IL-35) is a heterodimeric cytokine composed of EBI3 and IL-12p35 secreted by activated regulatory B cells and CD138+CD44highBlimp-1+ regulatory plasmablasts in draining lymph nodes during autoimmune inflammation (such as experimental autoimmune encephalomyelitis or uveitis) and intracellular bacterial infections (Salmonella). IL-35 binds to IL-12Rβ2/gp130 and IL-27Rα/IL-12Rβ2 receptors on effector T cells and B cells, activating STAT1 and STAT4/STAT3 to arrest TH1 and TH17 cell-cycle progression while inducing conventional B and T cells to secrete their own IL-35 and IL-10.
Why can anti-CD20 B-cell depletion therapy either worsen or improve autoimmune disease depending on timing?
Because CD20 is expressed on both pathogenic antigen-presenting memory B cells and protective CD20+ regulatory B cells (B10 and transitional Breg), pan-B-cell depletion removes both pro-inflammatory and anti-inflammatory populations. When anti-CD20 antibodies are administered during the early initiation phase of an immune response, loss of IL-10-producing B10 cells removes a key brake on dendritic cells and TH1/TH17 priming, worsening disease. Conversely, during established autoimmune disease, anti-CD20 therapy eliminates pathogenic memory B cells, and the bone marrow subsequently reconstitutes the periphery with newly emigrated CD24highCD38high transitional Breg cells, restoring the Breg-to-effector ratio and maintaining durable remission.
References
- Fillatreau, S., Sweenie, C. H., McGeachy, M. J., Gray, D., & Anderton, S. M. (2002). "B cells regulate autoimmunity by provision of IL-10." Nature Immunology, 3(10), 944–950. https://doi.org/10.1038/ni833
- Yanaba, K., Bouaziz, J.-D., Haas, K. M., Poe, J. C., Fujimoto, M., & Tedder, T. F. (2008). "A regulatory B cell subset with a unique CD1dhiCD5+ phenotype controls T cell-dependent inflammatory responses." Immunity, 28(5), 639–650. https://doi.org/10.1016/j.immuni.2008.03.017
- Shen, P., Roch, T., Lampropoulou, V., O'Connor, R. A., Stervbo, U., Hilgenberg, E., Ries, S., Dang, V. D., Jaimes, Y., Daridon, C., Li, R., Jouneau, L., Boudinot, P., Wilantri, S., Sakwa, I., Mauri, C., Steinbrink, K., & Fillatreau, S. (2014). "IL-35-producing B cells are critical regulators of immunity during autoimmune and infectious diseases." Nature, 507(7492), 366–370. https://doi.org/10.1038/nature12979
- Rosser, E. C., & Mauri, C. (2015). "Regulatory B cells: origin, phenotype, and function." Immunity, 42(4), 607–612. https://doi.org/10.1016/j.immuni.2015.04.005